X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with GSK Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs GSK PHARMA - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS GSK PHARMA NOVARTIS/
GSK PHARMA
 
P/E (TTM) x 389.3 64.6 602.3% View Chart
P/BV x 19.2 10.4 184.6% View Chart
Dividend Yield % 1.5 1.2 123.5%  

Financials

 NOVARTIS   GSK PHARMA
EQUITY SHARE DATA
    NOVARTIS
Mar-16
GSK PHARMA
Mar-17
NOVARTIS/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs9823,838 25.6%   
Low Rs5562,637 21.1%   
Sales per share (Unadj.) Rs252.9354.2 71.4%  
Earnings per share (Unadj.) Rs62.139.8 156.3%  
Cash flow per share (Unadj.) Rs63.342.9 147.6%  
Dividends per share (Unadj.) Rs10.0030.00 33.3%  
Dividend yield (eoy) %1.30.9 140.3%  
Book value per share (Unadj.) Rs363.6236.9 153.5%  
Shares outstanding (eoy) m31.9684.70 37.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.09.1 33.3%   
Avg P/E ratio x12.481.4 15.2%  
P/CF ratio (eoy) x12.275.5 16.1%  
Price / Book Value ratio x2.113.7 15.5%  
Dividend payout %16.175.4 21.3%   
Avg Mkt Cap Rs m24,580274,216 9.0%   
No. of employees `0000.84.7 16.0%   
Total wages/salary Rs m1,8014,830 37.3%   
Avg. sales/employee Rs Th10,748.96,387.0 168.3%   
Avg. wages/employee Rs Th2,395.21,028.3 232.9%   
Avg. net profit/employee Rs Th2,641.1717.1 368.3%   
INCOME DATA
Net Sales Rs m8,08330,000 26.9%  
Other income Rs m829728 113.9%   
Total revenues Rs m8,91330,728 29.0%   
Gross profit Rs m2344,190 5.6%  
Depreciation Rs m37263 14.0%   
Interest Rs m20-   
Profit before tax Rs m1,0254,655 22.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m170-   
Extraordinary Inc (Exp) Rs m1,696457 371.2%   
Tax Rs m7521,744 43.1%   
Profit after tax Rs m1,9863,368 59.0%  
Gross profit margin %2.914.0 20.7%  
Effective tax rate %73.437.5 195.8%   
Net profit margin %24.611.2 218.9%  
BALANCE SHEET DATA
Current assets Rs m12,67816,742 75.7%   
Current liabilities Rs m2,4337,202 33.8%   
Net working cap to sales %126.731.8 398.6%  
Current ratio x5.22.3 224.2%  
Inventory Days Days3352 63.1%  
Debtors Days Days2221 108.2%  
Net fixed assets Rs m698,635 0.8%   
Share capital Rs m160847 18.9%   
"Free" reserves Rs m11,46019,222 59.6%   
Net worth Rs m11,62120,069 57.9%   
Long term debt Rs m010 0.0%   
Total assets Rs m14,40030,038 47.9%  
Interest coverage x570.5NM-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.61.0 56.2%   
Return on assets %13.811.2 123.1%  
Return on equity %17.116.8 101.8%  
Return on capital %23.625.5 92.6%  
Exports to sales %0.70-   
Imports to sales %18.60-   
Exports (fob) Rs m60NA-   
Imports (cif) Rs m1,503NA-   
Fx inflow Rs m186528 35.3%   
Fx outflow Rs m1,8217,193 25.3%   
Net fx Rs m-1,635-6,665 24.5%   
CASH FLOW
From Operations Rs m2,5312,360 107.2%  
From Investments Rs m-8,2703,008 -274.9%  
From Financial Activity Rs m-386-5,108 7.6%  
Net Cashflow Rs m-6,125260 -2,352.9%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 50.7 147.9%  
Indian inst/Mut Fund % 2.0 10.2 19.6%  
FIIs % 1.6 23.8 6.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 15.4 139.6%  
Shareholders   41,647 102,036 40.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   DR. REDDYS LAB  STERLING BIOTECH  NATCO PHARMA  AUROBINDO PHARMA  IPCA LABS  

Compare NOVARTIS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Of Crash in Bitcoin, Correction in MidCap and SmallCap Indices and Top Stocks in Action Today(Pre-Open)

The past year has seen the BSE MidCap and BSE SmallCap indices surging by 43.1% and 57.1% respectively. Taking a two year view these indices have produced mind-boggling return of 75.3% .

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jan 17, 2018 09:07 AM

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - ORCHID PHARMA LTD COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS